Xilio Therapeutics (XLO) Accumulated Expenses (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Accumulated Expenses data on file, last reported at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 131.01% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.0 million (up 131.01% YoY), and the FY2025 full-year result was $11.7 million, up 17.61% from the prior year.
• Accumulated Expenses retreated to $9.0 million in Q1 2026, from $11.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.1 million in Q2 2022 to a low of $15000.0 in Q3 2024.
• A 5-year average of $8.2 million and a median of $9.0 million in 2026 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses slumped 99.84% in 2024 and jumped 59580.0% in 2025, its largest moves.
• Tracing XLO's Accumulated Expenses over 5 years: stood at $10.3 million in 2022, then climbed by 1.65% to $10.5 million in 2023, then slipped by 4.92% to $10.0 million in 2024, then increased by 17.61% to $11.7 million in 2025, then fell by 23.59% to $9.0 million in 2026.
• Business Quant data shows XLO's Accumulated Expenses at $9.0 million in Q1 2026, $11.7 million in Q4 2025, and $9.0 million in Q3 2025.